Safety, tolerability, pharmacokinetics(PK) and pharmacodynamics(PD) of HSK31858,a novel DPP-1 inhibitor in healthy volunteers:a phase I clinical trial

被引：0
|
作者：
Hou, Jie [1 ]
Guan, Wei Jie [2 ]
Li, Fang Qiong [3 ]
Zeng, Wei Fang [3 ]
Liu, Han Mo [3 ]
机构：
[1] PKUcare Luzhong Hosp, Zibo, Peoples R China
[2] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China
[3] Haisco Pharmaceut Grp Co Ltd, Chengdu, Peoples R China
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA2836
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
    Ogata, Koichiro
    Mendell-Harary, Jeanne
    Tachibana, Masaya
    Masumoto, Hiroshi
    Oguma, Toshihiro
    Kojima, Masazumi
    Kunitada, Satoshi
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (07): : 743 - 753
  • [2] Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
    Zou, Chan
    Zuo, Xiaocong
    Huang, Jie
    Hua, Ye
    Yang, Shuang
    Yang, Xiaoyan
    Guo, Can
    Tan, Hongyi
    Chen, Jun
    Chu, Zhaoxing
    Pei, Qi
    Yang, Guoping
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [3] Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
    Yap, Desmond Y. H.
    Hai, Jojo
    Lee, Paul C. H.
    Zhou, Xueying
    Lee, Michael
    Zhang, Yu
    Wang, Meng
    Chen, Xiaoxiang
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 1769 - 1779
  • [4] Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Teneligliptin, a New DPP-IV Inhibitor, in Healthy Volunteers
    Kumagai, Yuji
    Fujita, Tomoe
    Kawaguchi, Atsuhiro
    Hayashi, Yoshiharu
    Kondou, Kazuoki
    [J]. DIABETES, 2010, 59 : A193 - A193
  • [5] PHASE I TRIAL OF PYRAGREL, A NOVEL THROMBOXANE SYNTHETASE INHIBITOR, TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS IN HEALTHY VOLUNTEERS.
    Zou, C.
    Huang, J.
    Pei, Q.
    Yang, G.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S78 - S78
  • [6] A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
    Susanne Johansson
    David P. Rosenbaum
    Mikael Knutsson
    Maria Leonsson-Zachrisson
    [J]. Clinical and Experimental Nephrology, 2017, 21 : 407 - 416
  • [7] Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
    Al-Karagholi, Mohammad Al-Mandi
    Hansen, Jakob Moller
    Abou-Kassem, Dalia
    Hansted, Anna Koldbro
    Ubhayasekera, Kumari
    Bergquist, Jonas
    Vecsei, Laszlo
    Jansen-Olesen, Inger
    Ashina, Messoud
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (02):
  • [8] A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
    Johansson, Susanne
    Rosenbaum, David P.
    Knutsson, Mikael
    Leonsson-Zachrisson, Maria
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2017, 21 (03) : 407 - 416
  • [9] Safety, Tolerability, Pharmacokinetics (pk) And Pharmacodynamics (pd) Of Gsk2339345-Novel Sodium Channel Blocker. Results From Two Phase I Studies In Healthy Volunteers
    Marks-Konczalik, J.
    Murdoch, R. D.
    Kelly, K. L.
    Cheesbrough, A.
    Siederer, S. K.
    Singh, D.
    Smith, J. A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [10] CFZ533: SAFETY, TOLERABILITY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF A NOVEL ANTI-CD40 ANTIBODY IN HEALTHY VOLUNTEERS
    Slade, Alan
    Koo, Philip
    Espie, Pascal
    Rush, James
    Tomek, Charles
    Haraldsson, Boerje
    Klupp, Jochen
    [J]. TRANSPLANT INTERNATIONAL, 2015, 28 : 492 - 492
12345